Concentration-dependent effects of proteasomal inhibition on tau processing in a cellular model of tauopathy

International Journal of Clinical and Experimental Pathology

Volumn 2, Issue 6, 2009, Pages 561-573

  Hamano, Tadanori ^a   Gendron, Tania F ^a   Ko, Li Wen ^a   Yen, Shu Hui ^a  

^a MAYO CLINIC   (United States)

Author keywords

Calpain; Caspase; Cell culture; Inducible transfectant; Proteasomal inhibition; Tau degradation and aggregation

Indexed keywords

EID: 67650222406     PISSN: None     EISSN: 19362625     Source Type: Journal    
DOI: None     Document Type: Article

References (51)

1. Lee VM, Goedert M and Trojanowski JQ. Neurodegenerative tauopathies. Ann Rev Neurosci 2001;24:1121-1159.
2. Hutton M, Lewis J, Dickson D, Yen SH and McGowan E. Tauopathies with transgenic mice. Trends Mol Med 2001;7:467-470.
3. Friedhoff P, von Bergen M, Mandelkow EM and Mandelkow E. Structure of tau protein and assembly into paired helical filaments. Biochim Biophys Acta 2000;1502:122-132.
4. Goedert M, Jakes R, Spillantini MG, Hasegawa M, Smith MJ and Crowther RA. Assembly of microtubule-associated protein tau into Alzheimer-like filaments induced by sulphated glycosaminoglycans. Nature 1996;383:550-553.
5. Wilson DM and Binder LI. Free fatty acids stimulate the polymerization of tau and amyloid beta peptides. In vitro evidence for a common effector of pathogenesis in Alzheimer's disease. Am J Pathol 1997;150: 2181-2195.
6. Nacharaju P, Lewis J, Easson C, Yen S, Hackett J, Hutton M and Yen SH. Accelerated filament formation from tau protein with specific FTDP-17 missense mutations. FEBS Lett 1999;447: 195-199.
7. Abraha, Ghoshal N, Gamblin TC, Cryns V, Berry RW, Kuret J and Binder LI. C-terminal inhibition of tau assembly in vitro and in Alzheimer's disease. J Cell Sci 2000;113:3737-3745.
8. Yin H and Kuret J. C-terminal truncation modulates both nucleation and extension phases of tau fibrillization. FEBS Lett 2006; 6580:211-215.
9. Billinglsey, ML and Kincaid RL. Regulated phosphorylation and dephosphorylation of tau protein; effects on microtubule interaction, intracellular trafficking and neurodegeneration. Biochem J 1997;3234:577-591.
10. Keller JN, Hanni KB and Markesbery WR. Impaired proteasome function in Alzheimer's disease. J Neurochem 2000;75:436-439.
11. Lam YA, Pickart CM, Alban A, Landon M, Jamieson C, Ramage R, Mayer RJ and Layfield R. Inhibition of the ubiquitin-proteasome system in Alzheimer's disease. Proc Natl Acad Sci USA 2000;97:9902-9906.
12. Chung CW, Song YH, Kim IK, Yoon WJ, Ryu, BR, Jo DG, Woo HN, Kwon YK, Kim HH, Gwag BJ, Mook-Jung IH and Jung YK. Proapoptotic effects of tau cleavage product generated by caspase-3. Neurobiol Dis 2001;8:162-172.
13. Fasulo L, Ugolini G, Visintin M, Bradbury A, Brancolini C, Verzillo V, Novak M and Cattaneo A. The neuronal microtubule-associated protein tau is a substrate for caspase-3 and an effector of apoptosis. J Neurochem 2000;75: 624-633.
14. Gamblin TC, Chen F, Zambrano A, Abraha A, Lagalwar S, Guillozet AL, Lu M, Fu Y, Garcia-Sierra F, LaPointe N, Miller R, Berry RW, Binder LI and Cryns VL. Caspase cleavage of tau: linking amyloid and neurofibrillary tangles in Alzheimer's disease. Proc Natl Acad Sci USA 2003;100:10032-10037.
15. Johnson GV, Jope RS and Binder LI. Proteolysis of tau by calpain. Biochem Biophys Res Com 1989;163:1505-1511.
16. Yang LS, Gordon-Krajcer W and Ksiezak-Reding H. Tau released from paired helical filaments with formic acid or guanidine is susceptible to calpain-mediated proteolysis. J Neurochem 1997;69:1548-1558.
17. Yen S, Easson C, Nacharaju P, Hutton M and Yen SH. FTDP-17 tau mutations decrease the susceptibility of tau to calpain I digestion. FEBS Lett 1999;461:91-95.
18. Bednarski E and Lynch G. Cytosolic proteolysis of tau by cathepsin D in hippocampus following suppression of cathepsin B and L. J Neurochem 1996;67:1846-1855.
19. Kenessey A, Nacharaju P, Ko L and Yen SH. Degradation of tau by lysosomal enzyme cathepsin D: implication for Alzheimer neurofibrillary degeneration. J Neurochem 1997;69:2026-2038.
20. Bi X, Haque TS, Zhou J, Skillman AG, Lin B, Lee CE, Kuntz ID, Ellman JA and Lynch G. Novel cathepsin D inhibitors block the formation of hyperphosphorylated tau fragments in hippocampus. J Neurochem 2000;74:1469-1477.
21. David DC, Layfield R, Serpell L, Narain Y, Goedert M and Spillantini MG. Proteasomal degradation of tau protein. J Neurochem 2002;83:176-185.
22. Cardozo C and Michaud C. Proteasome-mediated degradation of tau proteins occurs independently of the chymotrypsin-like activity by a non-processive pathway. Arch Biochem Biophys 2002;408:103-110.
23. Johnson GV. Tau phosphorylation and proteolysis: insights and perspectives. J Alzheimers Dis 2006;9:243-250.
24. Feuillette S, Blard O, Lecourtois M, Frebourg T, Campion D and Dumanchin C. Tau is not normally degraded by the proteasome. J Neurosci Res 2005;80:400-405.
25. Delobel P, Leroy O, Hamdane M, Sambo AV, Delacourte A and Buee L. Proteasome inhibition and Tau proteolysis: an unexpected regulation. FEBS Lett 2005;579:1-5.
26. Brown MR, Bondada V, Keller JN, Thorpe J and Geddes JW. Proteasome or calpain inhibition does not alter cellular tau levels in neuroblastoma cells or primary neurons. J Alzheimers Dis 2005;7:15-24.
27. Shimura H, Schwartz D, Gygi SP and Kosik KS. CHIP-Hsc70 complex ubiquitinates phosphorylated tau and enhances cell survival. J Biol Chem 2004;279:4869-4876.
28. Zhang YJ, Xu YF, Liu XH, Li D, Yin J, Liu YH, Chen XQ and Wang JZ. Carboxyl terminus of heat-shock cognate 70-interacting protein degrades tau regardless its phosphorylation status without affecting the spatial memory of the rats. J Neural Transmission 2008;115:483-491.
29. Dickey CA, Yue M, Lin WL, Dickson DW, Dunmore JH, Lee WC, Zehr C, West G, Cao S, Clark AM, Caldwell GA, Caldwell KA, Eckman C, Patterson C, Hutton M and Petrucelli L. Deletion of the ubiquitin ligase CHIP leads to the accumulation, but not the aggregation, of both endogenous phospho- and caspase-3-cleaved tau species. J Neurosci 2006;26: 6985-6996.
30. Sahara N, Murayama M, Mizoroki T, Urushitani M, Imai Y, Takahashi R, Murata S, Tanaka K and Takashima A. In vivo evidence of CHIP up-regulation attenuating tau aggregation. J Neurochem 2005;94:1254-1263.
31. Dickey CA, Dunmore J, Lu B, Wang JW, Lee WC, Kamal A, Burrows F, Eckman C, Hutton M and Petrucelli L. HSP induction mediates selective clearance of tau phosphorylated at proline-directed Ser/Thr sites but not KXGS (MARK) sites. FASEB J 2006;20:753-755.
32. Keck S, Nitsch R, Grune T and Ullrich O. Proteasome inhibition by paired helical filament-tau in brains of patients with Alzheimer's disease. J Neurochem 2003;85: 115-122.
33. Ko L, Rush T, Sahara N, Kersh JS, Easson C, DeTure M, Lin WL, Connor YD and Yen SH. Assembly of filamentous tau aggregates in human neuronal cells. J Alzheimers Dis 2004; 6:605-622.
34. Ko L, DeTure M, Sahara N, Chihab R, Vega IE and Yen SH. Recent advances in experimental modeling of the assembly of tau filaments. Biochim Biophys Acta 2005;1739:125-139.
35. Hamano T, Gendron TF, Causevic E, Yen SH, Lin WL, Isidoro C, Deture M and Ko LW. Autophagic-lysosomal perturbation enhances tau aggregation in transfectants with induced wild-type tau expression. Eur J Neurosci 2008; 27:1119-1130.
36. Sahara N, Lewis J, DeTure M, McGowan E, Dickson DW, Hutton M and Yen SH. Assembly of tau in transgenic animals expressing P301L tau: alteration of phosphorylation and solubility. J Neurochem 2002;83:1498-1508.
37. DeTure M, Ko L, Easson C and Yen SH. Tau assembly in inducible transfectants expressing wild-type or FTDP-17 tau. Am J Pathol 2002; 161;1711-1722.
38. Gendron TF, McCartney S, Causevic E, Ko L and Yen SH. Ethanol enhances tau accumulation in neuroblastoma cells that inducibly express tau. Neurosci Lett 2008; 443:67-71.
39. Brancolini C, Lazarevic D, Rodriguez J and Schneider C. Dismantling cell-cell contacts during apoptosis is coupled to a caspase-dependent proteolytic cleavage of beta-catenin. J Cell Biol 1997; 139:759-771.
40. Vanags DM, Pön-Ares MI, Coppola S, Burgess DH and Orrenius S. Protease involvement in fodrin cleavage and phosphatidylserine exposure in apoptosis. J Biol Chem 1996;271: 31075-31085.
41. Pike BR, Flint J, Dutta S, Johnson E, Wang KK and Hayes RL. Accumulation of non-erythroid alpha II-spectrin and calpain-cleaved alpha II-spectrin breakdown products in cerebrospinal fluid after traumatic brain injury in rats. J Neurochem 2001;78:1297-1306.
42. Hideshima T, Richardson P, Chauhan D, Palombella VJ, Elliott PJ, Adams J and Anderson KC. The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res 2001;61:3071-3076.
43. Lang-Rollin I, Vekrellis K, Wang Q, Rideout HJ and Stefanis L. Application of proteasomal inhibitors to mouse sympathetic neurons activates the intrinsic apoptotic pathway. J Neurochem 2004;90:1511-1544.
44. Suh J, Lee YA and Gwag BJ. Induction and attenuation of neuronal apoptosis by proteasome inhibitors in murine cortical cell cultures. J Neurochem 2005;95:684-694.
45. Sun X, Gulyas M, Hjerpe A and Dobra K. Proteasome inhibitor PSI induces apoptosis in human mesothelioma cells. Cancer Lett 2006; 232:161-169.
46. Anan A, Baskin-Bey ES, Bronk SF, Werneburg NW, Shah VH and Gores GJ. Proteasome inhibition induces hepatic stellate cell apoptosis. Hepatology 2006;43:335-344.
47. Rami A, Volkmann T, Agarwal R, Schooninger S, Nurnberger F, Saido TC and Winckler J. β2-adrenergic receptor responsivenss of the calpain-calpastatin system and attenuation of neuronal death in rat hippocampus after transient global ischemia. Neurosci Res 2003; 47:373-383.
48. Rissman RA, Poon WW, Blurton-Jones, M, Oddo S, Torp R, Vitek MP, LaFerla FM, Rohn TT and Cotman CW. Caspase-cleavage of tau is an early event in Alzheimer's disease tangle pathology. J Clin Invest 2004;114:121-130.
49. Guillozet-Bongaarts AL, Garcia-Sierra F, Reynolds MR, Horowitz PM, Fu Y, Wang T, Cahill ME, Bigio EH, Berry RW and Binder LI. Neurobiol Aging 2005;26:1015-1022.
50. Cotman CW, Poon WW, Rissman RA and Blurton-Jones M. The role of caspase cleavage of tau in Alzheimer's disease neuropathology. J Neuropathol Exp Neurol 2005;64:104-112.
51. Cecarini V, Ding Q and Keller JN. Oxidative inactivation of the proteasome in Alzheimer's disease. Free Radical Res 2007;41:673-680.